UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25 SEC FILE NUMBER
0-9065
NOTIFICATION OF LATE FILING
CUSIP NUMBER
38114510 1
(Check One): Form 10-K Form 20-F Form 11-K (X) Form 10-Q
Form N-SAR
For Period Ended: May 31, 1996
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended:
If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:
PART I REGISTRANT INFORMATION
Golden Pharmaceuticals, Inc.
Full Name of Registrant
Former Name if Applicable
1313 Washington Avenue
Address of Principal Executive Office (Street and Number)
Golden, Colorado 80401
City, State and Zip Code
PART II RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate)
(a) The reasons described in reasonable detail in Part III of this
form could not be eliminated without unreasonable effort or
expense;
(X) (b) The subject annual report, semi-annual report, transition report on
Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof, will be
filed on or before the fifteenth calendar day following the
prescribed due date; or the subject quarterly report of transition
report on Form 10-Q, or portion thereof will be filed on or before
the fifth calendar day following the prescribed due date; and
(c) The accountant's statement or other exhibit required by Rule 12b-25(c)
has been attached if applicable.
PART III NARRATIVE
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q,
N-SAR, or the transition report or portion thereof, could not be filed within
the prescribed time period.
Please See Attached.
PART IV OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
Glen H. Weaver (303) 279-9375
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months or for such shorter period that
the registrant was required to file such report(s) been filed?
If answer is no, identify report(s).
(X) Yes No
(3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected
by the earnings statements to be included in the subject report or
portion thereof?
(X) Yes No
If so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
Golden Pharmaceuticals, Inc.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date July 16, 1996 By /s/ Glen H. Weaver
Glen H. Weaver, Vice President, Finance
INSTRUCTION: The form may be signed by an executive officer of the registrant
or by any other duly authorized representative. The name and title of the
person signing the form shall be typed or printed beneath the signature. If
the statement is signed on behalf of the registrant by an authorized
representative (other than an executive officer), evidence of the
representative's authority to sign on behalf of the registrant shall be filed
with the form.
ATTENTION
Intentional misstatements or omissions of fact constitute Federal Criminal
Violations (See 18 U.S.C. 1001).
GENERAL INSTRUCTIONS
1. This form is required by Rule 12b-25 (17 CFR 240.12b-25) of the General
Rules and Regulations under the Securities Exchange Act of 1934.
2. One signed original and four conformed copies of this form and amendments
thereto must be completed and filed with the Securities and Exchange
Commission, Washington, D.C. 20549, in accordance with Rule 0-3 of the
General Rules and Regulations under the Act. The information contained
in or filed with the form will be made a matter of public record in the
Commission files.
3. A manually signed copy of the form and amendments thereto shall be filed
with each national securities exchange on which any class of securities
of the registrant is registered.
4. Amendments to the notifications must also be filed on form 12b-25 but need
not restate information that has been correctly furnished. The form
shall be clearly identified as an amended notification.
5. Electronic Filers. This form shall not be used by electronic
filers unable to timely file a report solely due to electronic
difficulties. Filers unable to submit a report within the
time period prescribed due to difficulties in electronic filing should
comply with either Rule 201 or Rule 202 of Regulation S-T
(232.201 or 232.202 of this chapter) or apply for an adjustment in filing
date pursuant to Rule 13(b) of Regulation S-T (232.13(b) of
this chapter).<PAGE>
PART III - NARRATIVE
On August 7, 1995, the Registrant acquired all of the outstanding capital
stock of Quality Care Pharmaceuticals, Inc., a California corporation
(the "Acquisition"). As a result of difficulties encountered in connection
with the consolidation of the operations of QCP, the Registrant has to make
extensive adjustments to the financial statements for the quarter ended
May 31, 1996. Therefore the Registrant is unable to timely complete the
information required for the presentation of its Quarterly Report on
Form 10-QSB for the quarter ended May 31,1996.
PART IV - OTHER INFORMATION
3. The Acquisition has had a significant impact on the results of
operations of the Registrant. Anticipated condensed financial
information for the Registrant for the three months ended May 31 is
as follows:
1996 1995
Results of Operations
Revenues $ 2,627,886 $ 941,491
Costs and expenses 2,903,302 731,408
Net Income ($ 275,416) $ 210,083
Net Income per common share $ * $ 0.01
_____________
* Less than $.01 per share
